Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ThirdRockV
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ThirdRockV
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Third Rock Ventures proslijedio/la je Tweet
We're excited to announce a new strategic research focus on regenerative medicine approaches for the inner ear, including a collaboration and option agreement with The Rockefeller University to license a novel series of small-molecule LATS inhibitors: http://bit.ly/37DJehE pic.twitter.com/nNJUV1BLt3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"The growth is where the real innovation is, and where you can make a real difference in the patients' lives." TRV partner Abbie Celniker and
@mariabartiromo discussed the future of biotech investing and key areas of progress in the industry. https://bit.ly/2sn9U71#JPM20Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Partner Abbie Celniker live with
@MariaBartiromo at#JPM20 discussing innovation and the science and technologies we are excited about.@FoxBusinesspic.twitter.com/LiG4gylZot
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
GM from
#SanFrancisco join us from#JPMHC20@MorningsMaria@FoxBusiness 6-9am et#Exclusive w@jpmorgan ceo Dimon. +@dagenmcdowell@lizpeek@RoySchoenberg@AmericanWell@gen_jackkeane@ThirdRockV@EconomistChan@jpmorgan@RJHCUSTBC@EsperionInc@Merck@Varneyco@RandPaulHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to
@BlueprintMeds on receiving FDA approval for AYVAKIT, the 1st approved precision therapy for GIST & the only highly active treatment for a specific mutation of GIST. What a great day for patients & their families awaiting new treatment options. https://bit.ly/39XAl42 pic.twitter.com/S7gEImIVOF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
Today, we received
@US_FDA approval for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (#GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Learn more: http://bit.ly/2R0aKyZ pic.twitter.com/wiCSqHjsL2
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
We’re excited to announce a research collaboration with
@AcceleronPharma to identify small molecules designed to modulate genetic pathways associated with an indication in#pulmonarydisease. Learn more about our partnership here:http://ow.ly/oAos50xJV4KHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@RheosRx, a company translating insights in immunometabolism into novel treatments for immune-mediated diseases and cancer, announced a collaboration with@Roche today. Congrats to the team!https://twitter.com/Rheosrx/status/1207637625537990656 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
We’re pleased to announce that we have filed a CTA in Europe for evaluation of NEO-PTC-01, a personal neoantigen-targeted T cell therapy candidate. We plan a Phase 1 trial in patients with metastatic melanoma who are refractory to checkpoint inhibitors.https://bit.ly/2S5uXFy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
Congratulations to Thrive Earlier Detection for winning the BlueCross BlueShield (BCBS) Data Innovation Challenge! As the winner, they will use BCBS
#HealthData to find innovative ways to detect cancer earlier at a more cost-effective price. http://bcbsa.co/6014TnwSw pic.twitter.com/rCl65KDhUo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Third Rock Ventures proslijedio/la je Tweet
Local charitable industry group Life Science Cares expanding https://www.bizjournals.com/boston/news/2019/12/03/local-charitable-group-life-science-cares.html?ana=TRUEANTHEMTWT_BO&taid=5de636f016deae000192e9a3&utm_campaign=trueAnthem%3A+New+Content+%28Feed%29&utm_medium=trueAnthem&utm_source=twitter …pic.twitter.com/gMJKAwro7N
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to
@GBT_news on receiving@US_FDA approval for Oxbryta - the first treatment that directly targets the root cause of#sicklecell disease. Great news for millions of patients around the world. Read more: https://bit.ly/2OkTi88 pic.twitter.com/2KiFus1o3X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@insitro’s approach combines biology and artificial intelligence with the aim of revolutionizing drug discovery.@Forbes interviewed CEO@DaphneKoller on her career path and what’s next for the company.https://bit.ly/2QvKBtmHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to
@bluebirdbio,@neon_tx and@SageBiotech for being named to the@BostonGlobe’s 2019 Top Places to Work in Massachusetts!pic.twitter.com/0mdWBILxCh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to all of
@FiercePharma’s Fiercest Women in Life Sciences, including Cedilla Therapeutics CEO Sandra Glucksmann and@insitro CEO@DaphneKoller !#FierceWILS https://bit.ly/2X5yd4d pic.twitter.com/bzL3qbEtYU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re proud of Barbara Weber and
@DaphneKoller for being recognized among@Endpts’s 20 extraordinary women in biopharma R&D. Thank you for all you do for patients! https://bit.ly/2NZzcPA pic.twitter.com/Z9QWNzRYqq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pliant Therapeutics is focused on discovering and developing novel therapies for the treatment of fibrosis. Today they announced a partnership with
@Novartis to develop and commercialize NASH therapies. Congrats to the teams! https://bit.ly/32T76eM pic.twitter.com/sUtxGJVWXN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are proud to have joined over 5,000 blood cancer survivors and supporters at
@LightTheNight. Thank you to@LLSusa for all you do!pic.twitter.com/8DMIhlTpSD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.